Status In progress
Process CDF Review
ID number 1644

Provisional Schedule

Committee meeting: 2 05 October 2021
Expected publication 15 December 2021

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors GlaxoSmithKline
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Target Ovarian Cancer
Professional groups Association of Cancer Physicians
  British Gynaecological Cancer Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
26 August 2021 - 17 September 2021 Appraisal consultation
03 August 2021 Committee meeting: 1
30 March 2021 In progress. Topic is in progress
30 March 2021 Invitation to participate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance